InfuSystem (INFU) Competitors

InfuSystem logo
$14.79 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$14.80 +0.02 (+0.10%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

INFU vs. CSTL, OMDA, FLGT, GMRS, and SBC

Should you buy InfuSystem stock or one of its competitors? InfuSystem's main competitors and comparable companies include Castle Biosciences (CSTL), Omada Health (OMDA), Fulgent Genetics (FLGT), GMR Solutions (GMRS), and SBC Medical Group (SBC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does InfuSystem compare to Castle Biosciences?

InfuSystem (NYSE:INFU) and Castle Biosciences (NASDAQ:CSTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

In the previous week, Castle Biosciences had 19 more articles in the media than InfuSystem. MarketBeat recorded 23 mentions for Castle Biosciences and 4 mentions for InfuSystem. Castle Biosciences' average media sentiment score of 0.59 beat InfuSystem's score of 0.24 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InfuSystem
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Castle Biosciences
5 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

InfuSystem has higher earnings, but lower revenue than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InfuSystem$144.44M2.05$870K$0.4532.87
Castle Biosciences$344.23M2.93-$24.16M-$0.77N/A

InfuSystem has a net margin of 1.12% compared to Castle Biosciences' net margin of -6.10%. InfuSystem's return on equity of 2.78% beat Castle Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
InfuSystem1.12% 2.78% 1.41%
Castle Biosciences -6.10%-4.89%-4.06%

InfuSystem has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 10.8% of InfuSystem shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

InfuSystem presently has a consensus price target of $17.50, indicating a potential upside of 18.32%. Castle Biosciences has a consensus price target of $46.50, indicating a potential upside of 41.98%. Given Castle Biosciences' higher possible upside, analysts plainly believe Castle Biosciences is more favorable than InfuSystem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InfuSystem
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Castle Biosciences
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

Summary

InfuSystem and Castle Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does InfuSystem compare to Omada Health?

InfuSystem (NYSE:INFU) and Omada Health (NASDAQ:OMDA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

71.1% of InfuSystem shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by insiders. Comparatively, 6.4% of Omada Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

InfuSystem presently has a consensus target price of $17.50, suggesting a potential upside of 18.32%. Omada Health has a consensus target price of $25.92, suggesting a potential upside of 78.86%. Given Omada Health's higher possible upside, analysts plainly believe Omada Health is more favorable than InfuSystem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InfuSystem
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Omada Health
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Omada Health had 1 more articles in the media than InfuSystem. MarketBeat recorded 5 mentions for Omada Health and 4 mentions for InfuSystem. InfuSystem's average media sentiment score of 0.24 beat Omada Health's score of 0.01 indicating that InfuSystem is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InfuSystem
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Omada Health
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

InfuSystem has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Omada Health has a beta of 2.13, meaning that its share price is 113% more volatile than the broader market.

InfuSystem has higher earnings, but lower revenue than Omada Health. InfuSystem is trading at a lower price-to-earnings ratio than Omada Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InfuSystem$144.44M2.05$870K$0.4532.87
Omada Health$260.21M3.45-$12.78M$0.2169.00

Omada Health has a net margin of 4.21% compared to InfuSystem's net margin of 1.12%. Omada Health's return on equity of 5.71% beat InfuSystem's return on equity.

Company Net Margins Return on Equity Return on Assets
InfuSystem1.12% 2.78% 1.41%
Omada Health 4.21%5.71%4.40%

Summary

Omada Health beats InfuSystem on 9 of the 16 factors compared between the two stocks.

How does InfuSystem compare to Fulgent Genetics?

InfuSystem (NYSE:INFU) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

InfuSystem has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InfuSystem$144.44M2.05$870K$0.4532.87
Fulgent Genetics$322.67M2.09-$60.51M-$3.09N/A

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

InfuSystem has a net margin of 1.12% compared to Fulgent Genetics' net margin of -27.53%. InfuSystem's return on equity of 2.78% beat Fulgent Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
InfuSystem1.12% 2.78% 1.41%
Fulgent Genetics -27.53%-5.66%-5.16%

InfuSystem has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

InfuSystem currently has a consensus price target of $17.50, indicating a potential upside of 18.32%. Fulgent Genetics has a consensus price target of $25.00, indicating a potential upside of 3.82%. Given InfuSystem's stronger consensus rating and higher probable upside, equities research analysts clearly believe InfuSystem is more favorable than Fulgent Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InfuSystem
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Fulgent Genetics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

In the previous week, Fulgent Genetics had 2 more articles in the media than InfuSystem. MarketBeat recorded 6 mentions for Fulgent Genetics and 4 mentions for InfuSystem. Fulgent Genetics' average media sentiment score of 0.84 beat InfuSystem's score of 0.24 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InfuSystem
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fulgent Genetics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

InfuSystem beats Fulgent Genetics on 10 of the 15 factors compared between the two stocks.

How does InfuSystem compare to GMR Solutions?

InfuSystem (NYSE:INFU) and GMR Solutions (NYSE:GMRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

InfuSystem has a net margin of 1.12% compared to GMR Solutions' net margin of 0.00%. InfuSystem's return on equity of 2.78% beat GMR Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
InfuSystem1.12% 2.78% 1.41%
GMR Solutions N/A N/A N/A

71.1% of InfuSystem shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

InfuSystem presently has a consensus target price of $17.50, indicating a potential upside of 18.32%. GMR Solutions has a consensus target price of $18.56, indicating a potential upside of 59.28%. Given GMR Solutions' higher possible upside, analysts plainly believe GMR Solutions is more favorable than InfuSystem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InfuSystem
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
GMR Solutions
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90

InfuSystem has higher revenue and earnings than GMR Solutions. GMR Solutions is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InfuSystem$144.44M2.05$870K$0.4532.87
GMR SolutionsN/AN/AN/A-$1.56N/A

In the previous week, GMR Solutions had 11 more articles in the media than InfuSystem. MarketBeat recorded 15 mentions for GMR Solutions and 4 mentions for InfuSystem. GMR Solutions' average media sentiment score of 0.81 beat InfuSystem's score of 0.24 indicating that GMR Solutions is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InfuSystem
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GMR Solutions
3 Very Positive mention(s)
8 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

InfuSystem beats GMR Solutions on 8 of the 13 factors compared between the two stocks.

How does InfuSystem compare to SBC Medical Group?

InfuSystem (NYSE:INFU) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

In the previous week, SBC Medical Group had 20 more articles in the media than InfuSystem. MarketBeat recorded 24 mentions for SBC Medical Group and 4 mentions for InfuSystem. SBC Medical Group's average media sentiment score of 0.62 beat InfuSystem's score of 0.24 indicating that SBC Medical Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InfuSystem
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
SBC Medical Group
7 Very Positive mention(s)
2 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

InfuSystem presently has a consensus target price of $17.50, indicating a potential upside of 18.32%. SBC Medical Group has a consensus target price of $10.00, indicating a potential upside of 61.81%. Given SBC Medical Group's higher probable upside, analysts clearly believe SBC Medical Group is more favorable than InfuSystem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InfuSystem
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
SBC Medical Group
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

SBC Medical Group has higher revenue and earnings than InfuSystem. SBC Medical Group is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InfuSystem$144.44M2.05$870K$0.4532.87
SBC Medical Group$173.61M3.66$50.99M$0.5012.36

InfuSystem has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by insiders. Comparatively, 81.7% of SBC Medical Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

SBC Medical Group has a net margin of 27.99% compared to InfuSystem's net margin of 1.12%. SBC Medical Group's return on equity of 18.47% beat InfuSystem's return on equity.

Company Net Margins Return on Equity Return on Assets
InfuSystem1.12% 2.78% 1.41%
SBC Medical Group 27.99%18.47%13.10%

Summary

SBC Medical Group beats InfuSystem on 11 of the 16 factors compared between the two stocks.

Get InfuSystem News Delivered to You Automatically

Sign up to receive the latest news and ratings for INFU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INFU vs. The Competition

MetricInfuSystemHealthcare Providers & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$296.29M$10.57B$7.74B$22.85B
Dividend YieldN/A2.54%2.46%3.79%
P/E Ratio246.5435.7734.1629.05
Price / Sales2.052.088.483.28
Price / Cash12.7923.3421.9315.51
Price / Book5.993.594.373.61
Net Income$870K$332.46M$3.52B$1.08B
7 Day Performance-3.21%-4.03%-5.43%-3.75%
1 Month Performance10.37%-1.76%-4.54%-2.50%
1 Year Performance58.69%18.97%-1.42%6.19%

InfuSystem Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INFU
InfuSystem
2.7335 of 5 stars
$14.79
flat
$17.50
+18.3%
+55.5%$296.29M$144.44M246.54473
CSTL
Castle Biosciences
2.9184 of 5 stars
$34.42
+0.1%
$46.50
+35.1%
-2.1%$1.06B$344.23MN/A1,048
OMDA
Omada Health
3.3786 of 5 stars
$15.06
-0.2%
$26.33
+74.9%
-27.7%$936.15M$260.21M71.86946
FLGT
Fulgent Genetics
1.8657 of 5 stars
$25.78
-1.4%
$30.50
+18.3%
-17.3%$730.60M$322.67MN/A1,315
GMRS
GMR Solutions
4.1113 of 5 stars
$10.95
-2.8%
$18.78
+71.5%
N/A$593.70M$5.88BN/A33,858

Related Companies and Tools


This page (NYSE:INFU) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners